Summary. An experimental model of phenformininduced lactic acidosis was established in rats. Following a subtotal nephrectomy, renal failure developed (serum creatinine 4.5 + 0.1 mg/100 ml and 2.8 • 0.l mg/100 ml on the 1st and 8th postoperative days respectively). Immediately after nephrectomy intra-peritoneal phcnformin treatment, 16 mg/day, was commenced. Lactic acidosis developed progressively within 8 days, or earlier in the rats with the most severe renal insufficiency. The metabolic pattern was very similar to that observed in diabetic patients with a biguanide-induced lactic acidosis: on the 8th day, 2 h after the last phenformin injection, blood lactate was 10.8 _ 1.0 mmol/1 (controls: 1.50 _+ 0.03); pyruvate was 0.56 • 0.06 mmol/l (controls: 0.10 • 0.01) and blood pH: 7.00 • 0.02 (vs 7.34 • 0.02); 3-hydroxybutyrate was 1.41 ___ 0.37 mmol/1 (vs 0.32 • 0.03); acetoacetate: 0.51 • 0.15 mmol/1 (vs 0.17 • 0.01), and free glycerol: 0.63 • 0.07 retool/1 (vs 0.14 • 0.02). Increased concentrations of alanine (1.66 • 0.26 mmol/l, vs 0.48 • 0.04 in controls) and low blood glucose levels (23 • 8 mg/ 100 ml vs 70 _ 2, after a 12 hours fast) accompanied the lactic acidosis in spite of high g!ucagon levels (2030 • 170 pg/ml vs 108 • 10 in controls) and low insulin/glucagon molar ratio (0.19 vs 6.9 in controls). Normal rats, treated with phenformin at same doses, and nephrectomized rats injected with saline served as controls and remained free of lactic acidosis. Hydroxyphenformin (16 rag/day) injected in nephrectomized rats, was biologically inactive.
The occurrence of lactic acidosis in diabetic patients is often associated with antecedent phenformin treatment. Renal failure is often superimposed [1] [2] [3] and pharmacological studies have shown that phenformin is to some extent detoxified in the liver and excreted mainly in the urine [4] [5] [6] [7] . However, the role of phenformin in lactic acidosis and the eventual intervention of renal failure in accumulation of the drug have been so far suspected rather than proved. The aim of the present work was to describe an animal model for the study of biguanide-induced lactic acidosis.
Methods

Experimental Procedures
Adult male Wistar rats (250-300 g) were anaesthetized using thiopental (50 mg/kg IP). Bipolar nephrectomy of the right kidney, removing two-thirds of renal tissue, was performed. A tie placed around the left renal vessels was exteriorized at the lumbar surface, then tightly ligated 3 days later under light ether anaesthesia [8] . Serum creatinine concentration was measured from the 1st to the 8th day after ligation, by a routine method. Phenformin treatment was started in the hours following ligation of the left renal vessels. Doses of phenformin 4 to 40 rag/rat/day were investigated. A single injection of 40 rag/rat was immediately followed by convulsions and death without any significant change of blood lactate and glucose. Daily injection of 4rag and 8rag/rat induced a definite rise of blood lactate after two 0012-186X/78/0014/0261/$01. 40 weeks of treatment in nephrectomized rats. A dose of 16 rag/rat/day (in 2 ml physiologic saline solution) was finally chosen because of its clear-cut metabolic effects within one week of treatment. Other nephrectomized rats were injected with 2 ml saline, or with 4-hydroxy-phenformin 16 mg/rat/day (kindly supplied by Dr. Beckmann, Chemie Griinenthal GmbH, Stolberg, West Germany). Control rats were shamoperated and similarly injected. Every second day, 2 hours after injections, blood samples (2 ml) were obtained by careful cardiac puncture, under light thiopental anaesthesia (20 mg/kg IP) in an attempt to minimize stress-induced hyperlactataemia. These samples were analyzed for substrates or hormone and pH determinations.
Blood Pressure and Temperature Measurements
Arterial blood pressure was measured every 15 min for 3 h after phenformin injection, on the 5th day of treatment. The carotid artery was cannulated under thiopental anaesthesia (50 mg/kg IP) and connected to an arterial pressure transducer (Hewlett Packard, 1280 B) and blood pressure module (H.P. 78205 A); venous blood samples were collected hourly for lactate and pyruvate determinations. Rectal temperature was measured hourly, for 6 h, in non-anaesthetized intact and lactic acidotic rats, using a telethermometer (Yellow Spring Scientific Instruments Co., Yellow Spring, Ohio, U. S. A.).
Substrate and Hormone Determinations
Blood was collected in chilled heparinized tubes and an aliquot immediately deproteinized in cold 30% (w/v) perchloric acid (PCA); the remainder was centrifuged at +4 ~ C and aliquots of plasma deproteinized in cold 7.5% (w/v) PCA. Unneutralized filtrates were immediately stored at -20 ~ C until analysis, which for pyruvate and acetoacetate was within 3 days. Under the conditions employed, no significant decrease in the concentration of substrates could be demonstrated for this time interval, provided that the samples were thawed only once, just before assay. Assay of lactate, pyruvate, alanine, ketone bodies and glycerol was by an enzymic fluorimetric method modified from published techniques [9] , using an Aminco fiuoromicrophotometer (American Instruments Co., Silver Spring, Md, U. S.A.) equipped with appropriate filters. Lactate [10] , pyruvate [11] , 3-hydroxybutyrate [12] and acetoacetate [13] were determined in blood filtrates, alanine [14] and glycerol [15] in plasma filtrates; glucose was assayed by the glucose-oxidase method [16] after deproteinization of blood with 0.16% (w/v) uranyl-acetate (0.1 ml blood/ml). Blood pH was determined within 10 min of drawing anaerobically heparinized samples, by use of a glass microelectrode (Radiometer, type E-5021 a, Copenhagen, Denmark).
Hormone Assays
Blood samples intended for hormone assays were collected in aprotinin (Iniprol R -Choay, Paris, France; 2,000 U/ml), centrifuged at +4 ~ C and kept frozen at -20 ~ C until assay. Glucagon and insulin were determined according to the radio-immunological method [17] with slight technical adaptations [18] [19] . Purified rat insulin and glucagon were used as standards (Novo Research Institute, Copenhagen, Denmark). The glucagon assay utilised the 30 K antiserum from Prof. R. H. Unger (Dallas, Texas, U.S.A.).
Conversion of 14C-Lactate into 14C-Glucose
Normal and nephrectomized rats were used, with and without phenformin treatment. In order to reach comparable blood lactate concentrations in all rats, control animals were given IV sodium lactate, a 2 ml bolus (2 mmol) prior to the injection of 14C-lactate, followed by an infusion of 6.5 ml (6.5 retool) over one hour. The blood lactate levels in control rats were stable from the 2nd min after lactate injection and were between 7 and 9 mmol/l. The lactic acidotic rats received IV sodium bicarbonate in molar and volume amounts similar to the sodium lactate load administered to control rats, in order to reach comparable blood pH and volaemic variations. Some intact rats were given glucagon (5 ~tg bolus then 16 ~tg over one hour), in order to reach plasma glucagon concentration comparable to that of lactic acidotic rats. Finally, a total of 5 groups of animals were used: normal rats, lactate-infused; normal rats, phenforrain-treated and lactate-infused; normal rats, lactateand glucagon-infused; nephrectomized rats, lactateinfused; nephrectomized rats, phenformin-treated and bicarbonate-infused.
Under light thiopental anaesthesia, catheterization of the carotid artery was performed for blood sampling, and of the dorsal vein of the penis for infusion. One ~tCi of L(U)14C-lactate (Amersham, Bucks, England; CFB 97, specific activity 29 mCi/ mmol) was injected IV, mixed with the bolus of unlabelled sodium lactate or bicarbonate.
Blood samples (0.2 ml), collected every 10 min for 30 rain, then at 60 min, were deproteinized with 2.51% ZnSO4 (w/v) and 2.62% Ba(OH)2 (w/v), 1 ml of each. Protein-free filtrates were immediately frozen at -20 ~ C. The a4C-glucose contained in pro-12 tein-free filtrates was separated from 14C-lactate 10 using a mixture of two ion-exchange resins: 400 mg Amberlite MB3 and 100 mg Dowex 50 WX8 [20] . a Recovery of 14C-glucose added to blood before pre-~-~ 6. E cipitation was 80%, whereas the recovery of added ~ 4 14C-lactate was less than 0.05%. An aliquot of the ~ -protein-free supernatant, before and after ion-~ 2-<, exchange resin treatment, was counted in 10 ml of 0-Bray's solution [21] using a scintillation spectrophotometer (Nuclear Chicago Mark I); external _~ 061 standards were used to correct for quenching.
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Lactate specific radioactivity (dpm/~tmol) was ~ o2 calculated for all times of sampling. The percent of administered radioactivity incorporated into glucose ,'-0 was calculated on the basis of an assumed "glucose space" of 30% body weight:
Percent to glucose = 100 x Glucose space (ml) • 14C-glucose in blood (dpm/ml) Administered radioactivity (dpm) Total production of glucose per 100 g body wt/h was calculated on the basis of an assumed "lactate space" of 60% of body wt:
Lactate space (ml) Percent administered RA converted to glucose 100 x x 2 body wt (g)
Results
Renal Function
Subtotal nephrectomy caused marked alteration of renal function, with serum creatinine 4.5 + 0.1 rag/ 100 ml on the 1st post-operative day and 2.8 _+ 0.1 mg/100 ml on the 8th day.
Metabolic Changes Following Phenformin Administration to Normal and Partially Nephrectomized Rats
In normal rats, phenformin administration for 8 days induced a slight but significant rise of blood lactate: from 1.07 + 0.04 to 1.50 + 0.03 mmol/1, and alanine: from 0.36 _+ 0.02 mmol/1 to 0.48 + 0.04 (p < 0.01). Blood pyruvate (0.10 + 0.01 retool/l), plasma glycerol (0.14 + 0.02 mmol/l) and pH (7.34 + 0.02) did not change significantly; 3-hydroxybutyrate rose significantly from 0.21 + 0.03 to 0.32 + 0.03 mmol/1 (p < 0.025) and acetoacetate from 0.12 + 0.00 to 0.17 + 0.01 mmol/l (p < 0.005). The L/P and 3-hydroxybutyrate/acetoacetate ratios did not vary significantly and remained in a range of 11 to 12 and 1.8 to 2.8 respectively. Blood glucose, Results are presented as mean _+ SEM. Circles (O) denote a significant difference with the corresponding value in phenformintreated control rats, (p < 0.001). Number of experiments are between parentheses after a 12 hours fasting period, was 70 _ 2 mg/ 100 ml; plasma insulin: 30 _+ 10 ~tU/ml and glucagon: 163 ___ 7 pg/ml, the insulin/glucagon molar ratio being in the normal range. All rats with renal failure (serum creatinine > 1.4 mg/100 ml) developed a lactic acidosis when phenformin was given. On the 8th day, blood lactate was 10.8 + 1.0 mmol/l; pyruvate 0.56 + 0.06 mmol/1 and blood pH 7.00 + 0.02 (Fig. 1) . The L/P ratio was increased: 18.6 + 3.4. Acetoacetate (0.51 ___ 0.10 mmol/l), 3-hydroxybutyrate (1.41 _ 0.37 mmol/1) and glycerol (0.63 _ 0.07 mmol/l were also increased (Fig. 2) and the 3-hydroxybutyrate/acetoacetate ratio was increased: 3.0 + 0.3. Alanine was extremely elevated: 1.66 + 0.26 mmol/l. Blood glucose, after a 12 h fast, was 23 + 8 mg/100 ml, and some rats developed convulsions. Plasma glucagon was extremely elevated: 2030 + 170 pg/ml; plasma insulin was 23 _+ 9 ~tU/ml and the insulin/glucagon molar ratio declined to 0.19 (Table 1) .
Lactic acidosis developed earlier in the rats with severe renal failure. Out of 30 nephrectomized rats treated with phenformin, which all developed lactic acidosis, 7 had a serum creatinine level between 4.3 
!
Daily changes in blood 3-hydroxybutyrate, acetoacetate and free glycerol in normal rats with (0) and without (O) phenforrain-treatment, nephrectomized rats with (A) and without (A) phenformin treatment. Results are presented as in Figure 1 and 11.6 rag/100 ml (mean 6.9 + 1.0): lactic acidosis (mean lactate 9 mmol/l) appeared within 3 days; the other 23 rats, with a serum creatinine level between 1.9 and 3.7 mg/100 ml (mean 2.5 + 0.1) developed lactic acidosis (mean lactate 8.3 mmol/l) after 6 days. Lactic acidosis never appeared in the rats with a serum creatinine level below 1.4 mg/100 ml. No significant change occurred in the nephrec- 
Relation between Metabolic Events and Physiological Changes in Lactic Acidotic Rats
Every daily IP injection of phenformin was followed, in the nephrectomized rats, by transient physical changes: hypothermia, coma, constriction of ear-vessels; the rats looked normal again after a few hours. These transient alterations became more and more severe with the progression of treatment; some rats in this group died 2 to 4 hours after injection before the 8th day. Blood pressure, lactate and pyruvate were measured before and for the 3 hours following phenformin injection, on the 6th day (Fig. 3 ). Blood pressure was significantly higher in the nephrectomized rats, before injection. It then fell in both groups, but remained above 11 mmHg in all rats. Blood lactate rose significantly from the 1st hour following injection in the lactic acidotic group, but not in the intact phenformin-treated rats; the L/P ratio did not vary significantly in either group, remaining between 12 and 14. A deep hypothermia occurred in the lactic acidotic rats: these rats did not return to a normal body temperature before the 6th hour following phenfomin injection. A strong negative correlation appeared between body temperature and blood lactate.
Incorporation of 14C-Lactate into Glucose
These experiments were performed on the 8th day of treatment. All normal animals, not treated with phenformin, had normal concentrations of glucose, lactate, and alanine in blood, when the incorporation experiments started (Table 1) . Infusion of sodium lactate produced blood lactate concentrations equivalent to those measured in the lactic acidotic rats. A significant rise in blood glucose and alanine occurred in these lactate-infused normal rats (p < 0.001 in both cases).
Treatment with phenformin for 8 days induced, in the non-nephrectomized animals, a significant rise in blood lactate, alanine, and plasma glucagon, at the beginning of experiments. Then IV lactate infusion induced a significantly higher rise in blood alanine than in untreated, lactate-infused rats.
In the nephrectomized rats, not treated with phenformin, infusion of sodium lactate induced changes in blood glucose, alanine and lactate very similar to those observed in normal rats not treated with phenformin. The nephrectomized rats, phenforrain-treated, displayed strikingly low blood glucose levels, associated with high lactate, alanine and plasma glucagon concentrations throughout the whole duration of experiments.
The specific activity of circulating lactate was very similar, 10 min after 14C-lactate injection, in the lactate-infused normal rats and in the nephrectomized phenformin-treated rats. However, it decreased more slowly in this latter group than in control rats (Fig. 4) .
Incorporation of 14C lactate into glucose was significantly lower (p < 0.001) in the nephrectomized phenformin-treated rats than in all other groups (Table 2 ). In the absence of phenformin-treatmcnt, the nephrectomized rats displayed no reductions in glucose production from lactate. Phenformin treat-ment in normal rats did not influence significantly the incorporation of 14C lactate into glucose.
Exogenous glucagon enhanced markedly glucose production from lactate in the normal rats infused with sodium lactate (Table 2) .
Discussion
A reproducible model of lactic acidosis was obtained in non diabetic rats, by the combination of experimental renal failure and treatment with phenformin. A pharmacological dosage of phenformin was necessary to induce lactic acidosis within one week, presumably because the rat metabolizes phenformin at a much higher rate than the guinea-pig and man [7, 22] ; furthermore, these experiments show that neither nephrectomy alone, nor phenformin-treatment by itself could have induced this metabolic syndrome. The pattern of this lactic acidosis was very similar to that observed in diabetic patients treated with biguanides, including high lactate, ketone and alanine levels, increased L/P and 3-hydroxybutyrate/ acetoacetate ratios, and low glucose concentrations, in spite of high glucagon and low insulin concentrations [2, [23] [24] [25] . These similarities suggest that this experimental lactic acidosis may have many metabolic processes in common with the human syndrome. Similar patterns were observed in other animal models for lactic acidosis [26, 27] .
Many features suggest an impairment of gluconeogenesis as major contributor to the increase in blood lactate. Incorporation of 14C-lactate into glucose was decreased by comparison with all control animals, and particularly those which had been infused with lactate and glucagon. Furthermore, in the normal rats treated with phenformin, the hyperglycaemic effect of IV sodium lactate infusion was no longer observed, in spite of slightly raised plasma glucagon levels. Inhibition of gluconeogenesis by phenformin has been widely documented in vitro [28] [29] [30] [31] . The range of concentration effective in vitro was 10 -3 to 10 -5 tool/l, i.e. that measured in the liver of lactic acidotic rats [3] . The predominant role of the kidney in excreting phenformin is well known [3] [4] [5] [6] [7] and accumulation of phenformin did occur in the lactic acidotic rats [3] ; a similar accumulation had been suggested from assay in patients with a biguanide-induced lactic acidosis [1-3, 32, 33] .
Impairment of gluconeogenesis and the role of biguanide accumulation, although presumably predominant, may not be exclusive factors. Acidosis induces large changes in organ blood flow, especially the kidney [34] , which is an important site of gluconeogenesis; acidosis also decreases lactate utilization by the liver. Whether IV sodium bicarbonate corrected these changes was not verified.
The specific activity of lactate after injection of 14C-lactate decreased more slowly in the lactic acidotic rats than in the lactate-infused control animals, indicating a decreased utilization of lactate rather than an increased production. An increased lactate production because of early shock following injection of phenformin seems improbable, since blood lactate was already higher than 4 mmol/1 at a time when mean blood pressure was still in the range of 120-130 mmHg. But relative hypotension and deep hypothermia may have favoured an increased lactate production, according to a self-aggravated process, as suggested in some human patients with a biguanideinduced lactic acidosis [2, 32] .
It must he kept in mind, finally, that quantitative interpretations of the results obtained using 14C-lactate are fraught with difficulties: 1) The sizes of glucose and lactate pools were assumed, not actually measured; the presence of acidosis itself may alter lactate distribution. 2) An oxaloacetate pool is common to both the oxidative pathway of the tricarboxylic cycle and the gluconeogenic pathway [35, 36] : this renders calculations from isotope results not fully valid about the net fate of the labelled metabolite.
Other metabolic disturbances, however, are consistent with the concept of a deeply impaired gluconeogenesis. High concentrations of alanine were present in all rats with an increased lactataemia, as has been observed in lactic acidotic patients [23, 24] . The rise in alanine, following high lactate concentration in blood, was greatest in phenformintreated rats and lowest in the glucagon-infused control rats, suggesting that synthesis of alanine was, for this C3 substrate, a major metabolic alternative to the synthesis of glucose, or more likely, alanine uptake by the liver was inhibited to as great an extent as uptake of lactate [24] .
The increased glycerol concentration may be explained by the impairment of gluconeogenesis and/ or increased lipolysis. The ketoacidosis with selective rise of 3-hydroxybutyrate, also typical of the biguanide-induced lactic or metabolic [2, 3, [23] [24] [25] [26] 32] acidosis, can hardly be explained solely by an increase in lipolysis or by the high glucagon levels: phenformin stimulates ketogenesis in the perfused rat liver in vitro [30] and causes hyperketonaemia in man [37] .
The numerous similarities between the rat syndrome and the human biguanide-induced lactic acidosis suggest that the rat model may be applied to further metabolic and therapeutic investigations related to human lactic acidosis. surements; Prof. T. Driieke for expert advice on subtotal nephrectomy.
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